Venkataraman Rajesh, Kotyal Basvanyappa Mahendrappa, Samanta Brajogopal, Yadla Mahalaxmi, Ravi Naga Amrutha, Neelamraju Jayanthi, Madempudi Ratna Sudha
Pharmacology, Adichunchanagiri University, Karnataka, IND.
Pediatrics, Adichunchanagiri Hospital and Research Center, Adichunchanagiri University, Karnataka, IND.
Cureus. 2025 Apr 7;17(4):e81856. doi: 10.7759/cureus.81856. eCollection 2025 Apr.
Infantile colic, characterized by excessive crying in healthy infants, presents a significant challenge for parents and healthcare providers. This study investigated the potential of ()UBLRu-87 in alleviating colic symptoms and enhancing parental quality of life (QOL) in eighty breastfed infants ≤4 months of age through a double-blind, placebo-controlled trial. The treatment group received UBL Ru-87 drops, whereas the placebo group received an identical-looking placebo. Over 28 days, the study assessed crying time, burping, facial flushing, and fussiness. Parental QOL was evaluated using a visual analog scale (VAS). Fecal samples were analyzed for microbial diversity before and after treatment. Results demonstrated a significant reduction in colic symptoms in the probiotic group, particularly in crying time. In addition, burping, fussiness, and facial flushing were reduced significantly in probiotic-treated infants. Responders (infants with a 50% reduction in crying time) were also significantly enhanced. Parents of infants in the probiotic group reported a considerable improvement in QOL. Fecal microbiome analysis indicated beneficial shifts in microbial composition in the probiotic group, including increased Bifidobacteria and Firmicutes, along with reduced harmful bacteria like , , and . In conclusion, the use of UBLRu-87 notably diminished colic symptoms and improved parental QOL. These results suggest that UBLR-87 holds promise as a therapeutic option for alleviating infantile colic pain by influencing gut microbiota.
婴儿腹绞痛以健康婴儿过度哭闹为特征，给家长和医护人员带来了重大挑战。本研究通过一项双盲、安慰剂对照试验，调查了（）UBLRu - 87对80名4个月及以下母乳喂养婴儿缓解腹绞痛症状和提高家长生活质量（QOL）的潜力。治疗组接受UBL Ru - 87滴剂，而安慰剂组接受外观相同的安慰剂。在28天内，该研究评估了哭闹时间、打嗝、面部潮红和烦躁程度。使用视觉模拟量表（VAS）评估家长的生活质量。在治疗前后对粪便样本进行微生物多样性分析。结果表明，益生菌组的腹绞痛症状显著减轻，尤其是哭闹时间。此外，接受益生菌治疗的婴儿打嗝、烦躁和面部潮红也显著减少。有反应者（哭闹时间减少50%的婴儿）也显著增加。益生菌组婴儿的家长报告生活质量有相当大的改善。粪便微生物组分析表明，益生菌组的微生物组成发生了有益变化，包括双歧杆菌和厚壁菌增加，以及诸如、和等有害细菌减少。总之，使用UBLRu - 87显著减轻了腹绞痛症状并改善了家长的生活质量。这些结果表明，UBLR - 87有望通过影响肠道微生物群成为缓解婴儿腹绞痛疼痛的一种治疗选择。
